Skip to main content
JEIL PHARMACEUTICAL CO.,LTD logo

JEIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 271980 ISIN · KR7271980005 KO Manufacturing
Open in API
Filings indexed 135 across all filing types
Latest filing 2021-03-15 Audit Report / Informat…
Country KR South Korea
Listing KO 271980

About JEIL PHARMACEUTICAL CO.,LTD

https://www.jeilpharm.co.kr/english/

JEIL PHARMACEUTICAL CO.,LTD. is a company engaged in the development, manufacturing, and distribution of pharmaceutical products. Its portfolio includes both finished drug products and Active Pharmaceutical Ingredients (APIs). The company produces a diverse range of dosage forms, such as solid medicines (tablets and capsules), patches, and injections, with a strategic focus on becoming a leading manufacturer of injection-based medicines. Committed to developing high-value products, the company operates KGMP-certified manufacturing facilities. Research and development activities are central to its operations, driven by its dedicated R&D center.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) titled '감사보고서 제출' (Submission of Audit Report). It provides the audit opinion, financial highlights (assets, liabilities, equity, profit/loss), and details regarding the external auditor (Samduk Accounting Corp). While it contains financial data, it is a standardized regulatory disclosure form announcing the completion and submission of the audit report rather than the full annual report document itself. Therefore, it is classified as an Audit Report / Information document. FY 2020
2021-03-15 Korean
사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for Jeil Pharmaceutical Co., Ltd. for the fiscal year 2020 (Jan 1, 2020 to Dec 31, 2020). It contains detailed financial statements (consolidated and separate), management discussion and analysis, auditor's opinion, and corporate governance information. This aligns with the definition of an Annual Report (10-K) in the provided schema, as it is the official yearly report covering company activity and full financial performance. FY 2020
2021-03-15 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Jeil Pharmaceutical Co., Ltd. It contains the agenda for the upcoming annual general meeting, including the approval of financial statements, dividend proposals, and director remuneration. It also includes detailed management information, such as board activity reports, business overviews, and financial statements (balance sheet, income statement, cash flow). This type of document is a standard proxy statement/information circular provided to shareholders to solicit votes for the AGM, which falls under the 'Proxy Solicitation & Information Statement' category.
2021-03-08 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Jeil Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the dividend record date, and the date of the board resolution. This fits the definition of a 'Notice of Dividend Amount' (DIV) as it provides specific details regarding dividend payments to shareholders.
2021-02-26 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Jeil Pharmaceutical. It outlines the date, location, and agenda items (financial statement approval, director remuneration). This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of the meeting and the items to be voted upon.
2021-02-26 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Jeil Pharmaceutical) announcing a significant change in financial structure (revenue or profit/loss structure change of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for preliminary financial results before the final audit report is issued. Since it provides key financial highlights and is a formal regulatory announcement of financial performance, it falls under the 'Earnings Release' category. FY 2020
2021-02-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.